Phase III research

David Reddy: delivery of new anti-malaria drugs to developing countries is vital in fight against the disease

David Reddy, Medicines for Malaria Venture’s chief executive officer, discusses developments in the fight against the disease ahead of World Malaria Day on 25 April.…

Nine-component HPV vaccine aims to prevent 90% of cervical cancers

Researchers have developed a new nine-component vaccine against human papillomavirus which they believe could increase overall protection against cervical cancers to 90%.…

Carfilzomib gives survival benefits to patients with relapsed multiple myeloma

Adding the proteasome inhibitor carfilzomib to lenalidomide plus dexamethasone, the standard treatment for patients with relapsed multiple myeloma, significantly improves outcomes.…

UK government to review access to new medicines and diagnostics

Plans may include integrating the health service with life sciences research to bring innovations to patients faster.…

Immune checkpoint inhibitors bring new hope to cancer patients

PD-1 and PD-L1 inhibitors induce a higher response rate across a wider range of tumours than other immunotherapies.…

Forces driving the evolution of biologics into biosimilars and biobetters

As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…

Adding bevacizumab to triple therapy improves outcome in colorectal cancer

Patient outcome is improved when bevacizumab is given with a triple- rather than a two-drug combination in metastatic colorectal cancer.…